Veterinary Medicines

EURICAN DAP LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION

Not authorised
  • Water for injection
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine adenovirus 2, strain DK13, Live
Download as PDF

Product identification

Medicine name:
EURICAN DAP LYOPHILISATE AND SOLVENT FOR SUSPENSION FOR INJECTION
Eurican DAP лиофилизат и разтворител за инжекционна суспензия
Active substance:
  • Water for injection
  • Canine distemper virus, strain BA5, Live
  • Canine parvovirus, strain CAG2, Live
  • Canine adenovirus 2, strain DK13, Live
Target species:
  • Dog
Route of administration:
  • Subcutaneous use

Product details

Active substance and strength:
  • Water for injection
    1.00
    millilitre(s)
    /
    1.00
    Dose
  • Canine distemper virus, strain BA5, Live
    10000.00
    cell culture infective dose 50
    /
    1.00
    Dose
  • Canine parvovirus, strain CAG2, Live
    79432.00
    cell culture infective dose 50
    /
    1.00
    Dose
  • Canine adenovirus 2, strain DK13, Live
    316.00
    cell culture infective dose 50
    /
    1.00
    Dose
Pharmaceutical form:
  • Lyophilisate and solvent for suspension for injection
Withdrawal period by route of administration:
  • Subcutaneous use
    • Dog
      • Not applicable
        no withdrawal period
Anatomical therapeutic chemical veterinary (ATCvet) codes:
  • QI07AD02
Legal status of supply:
  • Veterinary medicinal product subject to veterinary prescription
Authorisation status:
  • Surrendered
Authorised in:
  • Bulgaria
Package description:
  • Plastic box of 50 vials of lyophilisate (1 dose) and 50 vials of solvent (1 ml)
  • Plastic box of 10 vials of lyophilisate (1 dose) and 10 vials of solvent (1 ml)

Additional information

Entitlement type:
  • Marketing Authorisation
Legal basis of product authorisation:
  • Full application - Known active substance (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
  • Boehringer Ingelheim Animal Health France
Marketing authorisation date:
Manufacturing sites for batch release:
  • Boehringer Ingelheim Animal Health France
Responsible authority:
  • BFSA
Authorisation number:
  • 0022-2645
Date of authorisation status change:
Reference member state:
  • France
Procedure number:
  • FR/V/0305/001
How useful was this page?:
No votes yet
"Please do not include any personal data, such as your name or contact details. If you do, you consent to the processing of that data in accordance with EMA’s Privacy Statement concerning requests for information or access to documents. If you would like a reply from EMA, please Send a question to EMA instead."